New hope for rare liver disease: experimental drug shows promise in early trial
NCT ID NCT03333928
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tested an experimental drug called HTD1801 in 59 adults with primary sclerosing cholangitis (PSC), a rare liver disease. Participants received either a low dose, a high dose, or a placebo for 18 weeks. The main goal was to see if the drug could lower a key liver enzyme (ALP) linked to disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS (PSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona Liver Health
Chandler, Arizona, 85224, United States
-
Arizona Liver Health
Tuscon, Arizona, 85711, United States
-
Aspen Woods Clinic
Calgary, Alberta, T3H 0V5, Canada
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Cumberland Research Associates
Fayetteville, North Carolina, 28304, United States
-
Florida Research Institute
Lakewood Rch, Florida, 34211, United States
-
Fresno Clinical Research Center
Fresno, California, 93720, United States
-
Gastro One
Germantown, Tennessee, 38138, United States
-
Gastrointestinal Associates
Flowood, Mississippi, 39232, United States
-
Keck School of Medicine of USC
Los Angeles, California, 90033, United States
-
Mercy Medical Center
Baltimore, Maryland, 21202, United States
-
Michigan Medicine University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Mount Sinai - Icahn School of Medicine
New York, New York, 10029, United States
-
Pinnacle Clinical Research
Austin, Texas, 78746, United States
-
Pinnacle Clinical Research
San Antonio, Texas, 78229, United States
-
South Denver Gastroenterology, PC
Englewood, Colorado, 80113, United States
-
Swedish Medical Center
Seattle, Washington, 98104, United States
-
Toronto Centre for Liver Disease, Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
-
University of Colorado, Denver
Aurora, Colorado, 80045, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Washington
Seattle, Washington, 98104, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
-
Wake Forest Baptist Health
Winston-Salem, North Carolina, 27157, United States
-
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.